© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
XOMA Royalty Corp. (XOMA) stock remained unchanged at $40.17 a share on NASDAQ. The stock opened at $43.53, fluctuating between $39.87 to $43.53 during the session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 13, 2026 | 43.97 | 43.97 | 39.77 | 40.17 | 5.71M |
| Jul 10, 2026 | 44.73 | 44.79 | 43.87 | 44.22 | 295.65K |
| Jul 09, 2026 | 45.00 | 45.22 | 44.13 | 44.80 | 375.68K |
| Jul 08, 2026 | 43.81 | 45.19 | 43.81 | 45.00 | 255.34K |
| Jul 07, 2026 | 43.85 | 44.01 | 43.58 | 43.89 | 144.74K |
| Jul 06, 2026 | 43.11 | 44.00 | 42.91 | 43.85 | 209.01K |
| Jul 02, 2026 | 42.62 | 43.00 | 42.46 | 43.00 | 137.63K |
| Jul 01, 2026 | 42.50 | 42.75 | 42.24 | 42.62 | 124.64K |
| Jun 30, 2026 | 42.22 | 42.54 | 42.07 | 42.50 | 200K |
| Jun 29, 2026 | 42.34 | 42.34 | 42.01 | 42.15 | 368.06K |
| Jun 26, 2026 | 42.29 | 42.50 | 42.07 | 42.15 | 439.31K |
| Jun 25, 2026 | 42.18 | 42.23 | 42.01 | 42.20 | 122.05K |
| Jun 24, 2026 | 41.81 | 42.18 | 41.81 | 42.15 | 164.68K |
| Jun 23, 2026 | 41.09 | 42.15 | 40.76 | 41.95 | 134.94K |
| Jun 22, 2026 | 42.05 | 42.16 | 41.85 | 42.00 | 105.5K |
| Jun 18, 2026 | 41.90 | 41.98 | 41.60 | 41.89 | 88.33K |
| Jun 17, 2026 | 41.93 | 41.96 | 41.54 | 41.72 | 80.47K |
| Jun 16, 2026 | 41.94 | 42.07 | 41.78 | 41.78 | 133.63K |
| Jun 15, 2026 | 41.82 | 42.20 | 41.75 | 41.95 | 114.42K |
| Jun 12, 2026 | 41.80 | 41.90 | 41.67 | 41.79 | 129.4K |
XOMA Royalty Corp. functions as a specialist in aggregating biotechnology royalties, with its operations extending across Europe, the United States, and the Asia Pacific region. The company is dedicated to fostering advancements in human health by collaborating with biotechnology firms. Its core business model involves acquiring the anticipated future economic benefits, such as royalties and milestone payments, associated with pre-market therapeutic candidates that have already been licensed to pharmaceutical or biotechnology firms. The firm focuses its investments on early to mid-stage clinical assets, typically those in Phase 1 and 2 trials, selected for their robust commercial potential and because they are licensed to development partners. Its extensive portfolio currently encompasses around 70 distinct assets. The parent company, XOMA Corporation, established in 1981, has its main office in Emeryville, California.
| Employees | 14 |
| Beta | 0.86 |
| Sales or Revenue | $4.76M |
| 5Y Sales Change% | -0.345% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |